4 posts • Page 1 of 1
- Joined: April 19th, 2005, 7:01 pm
"...<em>Finally, all roads in Connecticut lead to Yale. The University engages in a boggling amount of medical research and teaching activity. Who pays for it? Here is a reported list of some of its corporate funding partners who engage in pharmaceutical-related business: Boehringer, Bristol-Myers, Roche, Merck, Ziopharm Oncology, Achillion, CuraGen Corp., Metrum Research Group and Orbi Med, a company that does asset management in the global health sciences sector and has $5 billion in assets.</em>
<em>A 2008 Archstone Consulting study concluded pharma companies added more than $14 billion to the Connecticut economy in that year. And Connecticut colleges and universities laid out about $600 million for bioscience research in 2008, which was 81 percent of their whole academic research-and-development pie.</em>
<em>Connecticut is a relatively small state. <strong>To have all these pharmaceutical titans converge on it (and especially at the States most famous institution, Yale) versus releasing one boys psychiatric-drug history (an event that could start a domino effect within the whole pharmaceutical industry), who is going to exert pressure? Who is going to play its cards? Who is going to call in favors to keep secrets?</strong></em>..."
0 people like this